Developments of New Inotropes for Treatment of Acute Heart Failure
Article Sidebar
Main Article Content
Abstract
Inotropes are essential life-saving drugs in the treatment of acute heart failure because the drugs increase cardiac output in patients with hypoperfusion and reduce the chance of end-organ damage. Drug action is dependent on its ability to bind to arterial or cardiac receptors. There are different adverse reactions among drugs in this group. Conventional adrenergic agonists have many adverse reactions such as ventricular arrhythmias and cardiac infarction. Therefore, a new class of inotropes not binding to adrenergic receptors has been developed in order to reduce the adverse reactions of the conventional drugs, including phosphodiesterase III inhibitors (milrinone and amrinone), and calcium sensitizer (levosimendan). The new class of drug is more effective and safer. At present, these new drugs are used as an alternative treatment for acute heart failure.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Phrommintikul A, Buakhamsri A, Janwanishstaporn S, Sanguanwong S, Suvachittanont N. Heart Failure Council of Thailand (HFCT) 2019 Heart failure guideline: Acute heart failure. J Med Assoc Thai 2019; 102: 373-9.
Li L, Liu R, Jiang C, Du X, Huffman M, Lam C, et al. Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. Eur J Heart Fail 2020; 22: 646-60.
Moleerergpoom W, Hengrussamee K, Piyayotai D, Jintapakorn W, Sukhum P, Kunjara-Na-Ayudhya R, et al. Predictors of in-hospital mortality in acute decompensated heart failure (Thai ADHERE). J Med Assoc Thai 2013; 96: 157-64.
Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail 2016; 18: 891-975.
Maack C, Eschenhagen T, Hamdani N, Heinzel F, Lyon A, Manstein D, et al. Treatments targeting inotropy. Eur Heart J 2019; 40: 3626-44.
Overgaad C, Dzavík V. Inotropes and vasopressors. Circulation 2008; 118: 1047-56.
Pharmaceutical and Therapeutic Committee Siriraj Hospital. High alert drugs. 4nd ed. Bangkok: Siriraj Hospital; 2017.
Bistola V, Chioncel O. Inotropes in acute heart failure. Continuing Cardiol Educ. 2017; 3: 107–16. doi: 10.1002/cce2.59.
Tacon C, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 2012; 38: 359-67.
Lowes D, Tsvetkova T, Eichhorn E, Gilbert E, Bristow M. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardio 2001; 81: 141-49.
Cuffe M, Califf R, Adams K, Benza R, Bourge R, Colucci W, et al. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure-OPTIME-CHF. JAMA 2002; 287: 1541-47.
Antila S, Sundberg S, Lehtonen L. Clinical pharmacology of levosimendan. Clin Pharmacoki net 2007; 46: 535-52.
Follath F, Cleland J, Just H, Papp J, Scholz H, Peuhkurinen K,et al. Efficacy and safety of intravenous levosimendan compared with dobuta mine in severe lowoutput heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196–202.
Mebazaa A, Nieminen M, Packer M, Cohen-Solal A, Kleber F, Pocock S, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007 297: 1883–91.
Packer M, Colucci W, Fisher L, Massie B, Teerlink J, Young J,et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013; 1: 103-11.
Harjola VP, Giannakoulas G, von Lewinski D, Matskeplishvili S, Mebazaa A, Papp Z, et al. Use of levosimendan in acute heart failure. Eur Heart J Suppl. 2018; 20(Suppl I): I2-I10.
Bistola V, Arfaras-Melainis A, Polyzogopoulou E, Ikonomidis I, Parissis J. Inotropes in acute heart failure: from guidelines to practical use: Therapeutic options and clinical practice. Card Fail Rev. 2019; 4: 133-9.
Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail 2020; 7: 3505–30.
